Cellerix has secured €27.2 million in a Series B financing round, co-led by Ysios Asset Management, LSP, and Ventech, to advance the development of its innovative stem cell therapies.

Target Company Overview

Cellerix is a leading biopharmaceutical company specializing in the clinical development and production of innovative medicines derived from adult stem cells. Recently, Cellerix successfully secured €27.2 million in an oversubscribed Series B financing round. This funding will primarily support the advancement of its lead product, Cx401, a stem cell therapy aimed at treating complex perianal fistulas, a condition that currently lacks effective treatment options in the market, which is projected to exceed €1.5 billion in Europe. Cellerix received Orphan Drug Designation for Cx401 in 2005 and has initiated a pivotal Phase III trial with expectations to reach the market by 2010.

In addition to Cx401, Cellerix is also developing Cx501, intended for skin regeneration, which has received Orphan Drug Designation and is currently in Phase II trials. The company is advancing further pipeline products such as Cx601 and Cx611, which are being prepared for preclinical development targeted at treating other medical conditions such as immune system disorders.

Industry Overview in Spain

The biopharmaceutical industry in Spain has seen significant growth over the past decade, driven by advancements in research and development, particularly in the field of regenerative medicine and stem cells. Spain has increasingly established itself as a hub f